Previous 10 | Next 10 |
Assay will help guide treatment decisions in cases of non-small cell lung cancer Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration has approved the company’s PD-L1 IHC 28-8 pharmDx for expanded use in non-small cell lung cancer (NSC...
Friday I stuck my neck out and got bullish because the charts told me so Naturally, I am now on guard for how the stock market will make a fool of me, since that’s what happens 60% or more of the time, or so it feels. Since the markets are closed, I like to summarize information fro...
There have been a number of stocks that have seen wild swings so far in 2020. There were stocks that saw price drops over 50% during the plunge in February and March and some of those same stocks have more than doubled off of their March lows. Trading stocks like that can certainly be exciting...
Bill Ackman's Pershing Square ( OTCPK:PSHZF ) takes new position in Blackstone (NYSE: BX ) and Park Hotels & Resorts (NYSE: PK ). More news on: Pershing Square Holdings, Ltd., The Blackstone Group Inc., Park Hotels & Resorts Inc., Financial stocks news, Consumer stocks news, T...
Sponsorship will enable advancements in cancer research Agilent Technologies Inc . (NYSE: A) announces that biotech startup Trilogy Sciences has been awarded an Agilent Golden Ticket at LabCentral , a leading biotech innovation hub based in Cambridge, Massachusetts. LabCentral is a sha...
This article is part of a series that provides an ongoing analysis of the changes made to William Von Mueffling’s 13F stock portfolio on a quarterly basis. It is based on Von Mueffling’s regulatory 13F Form filed on 04/30/2020. Please visit our Tracking William Von Mueffling's...
Overview Agilent Technologies is a good business protected by a strong moat with ample room to grow. Bill Ackman and Pershing Square initiated a position in Agilent late last year around the current share price, so I decided to take a more in-depth look to assess the potential. While I ...
New York City, NY: May 1, 2020 – Published via (Wired Release):- “Market.us presents a new report titled Drug Discovery Technologies Market: 2020 Research and New Innovations in Oil and Gas Sector. The prime objective of the report is to offer updates and information related to ...
Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration has approved the company’s PD-L1 IHC 22C3 pharmDx as a companion diagnostic (CDx) to identify patients with non-small cell lung cancer who are appropriate for first-line monotherapy with ...
Highlighting their ongoing commitment to sustainability Agilent Technologies Inc. (NYSE: A) announced today that it has become a top-level sponsor of My Green Lab , a nonprofit organization dedicated to improving the sustainability of scientific research. Run “for scien...
News, Short Squeeze, Breakout and More Instantly...
Agilent Technologies Inc. Company Name:
A Stock Symbol:
NYSE Market:
Agilent Technologies Inc. Website:
Technology helps high-throughput labs operate more efficiently Agilent Technologies Inc. (NYSE: A) today announced it has acquired Sigsense Technologies , a San Francisco, California-based startup that uses artificial intelligence and power monitoring to help optimize lab operatio...
Expands Agilent’s end-to-end biopharma solutions that accelerate drug discovery, development, and manufacturing Agilent Technologies Inc. (NYSE: A) today announced it has signed a definitive agreement to acquire BIOVECTRA, a leading specialized contract development and manufacturin...
2024-07-21 07:07:00 ET At long last, Europe has a space rocket, the Ariane 6, able to compete with SpaceX and its ubiquitous Falcon 9. The Ariane 6 isn't a reusable rocket, it arrived four years later than it was supposed to, and it probably costs about twice as much as a Falcon. But fo...